-
Potential Impacts of Participating in an HIV Cure-Related Trial With an Analytical Treatment Interruption on Partners: Qualitative Research Findings
Sep 9, 2025, 16:22 PM -
What Are the Biggest Value Drivers? A Comparison of the Relative Impacts of Six Novel Value Elements on Value Estimates Across Twelve Treatments Through Generalized Cost-Effectiveness Analyses
Sep 9, 2025, 16:22 PM -
Do Public Preferences Matter? Health-Economic Evaluation of Antineoplastic Medication Considering EQ-5D Value Sets From Several Countries
Sep 9, 2025, 16:22 PM -
Evaluating a Potential Link Between Alprazolam and Intracranial Aneurysm: A Pharmacovigilance and Bioinformatics Approach Through FAERS and Molecular Docking
Sep 9, 2025, 16:22 PM -
An Interactive R-Shiny Application for Budget Impact Modeling of Cell and Gene Therapies With Multiple Innovative Payment Scenarios
Sep 9, 2025, 16:22 PM -
Narrative Review of Total Quality-Adjusted Life Year (QALY) Gains From Oncology Medicines Reimbursed From 2020 To 2025 in Ireland
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model
Sep 9, 2025, 16:22 PM -
Impact of Cancer on the Burden of Caregiving in China, Japan, and EU5: National Health and Wellness Survey
Sep 9, 2025, 16:22 PM -
Evaluating the Societal and Economic Impact of Immunotherapy for Melanoma Treatment in Bulgaria
Sep 9, 2025, 16:22 PM -
The Impact of Intravesical Instillations on Quality of Life in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Sep 9, 2025, 16:22 PM -
Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany
Sep 9, 2025, 16:22 PM -
Comorbidities of Anxiety Disorders in Children and Adolescents in Germany: A Nationwide Representative Claims Data Analysis
Sep 9, 2025, 16:22 PM -
Impact of the Severity of Disease-Related Malnutrition on Healthcare Resource Utilization in Pediatric Patients 1 Year and Older
Sep 9, 2025, 16:22 PM -
Improvements in Scalp Outcomes With Roflumilast Foam 0.3% for Psoriasis of the Scalp and Body From the Phase 3 ARRECTOR Trial
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and France: Lessons for Poland
Sep 9, 2025, 16:22 PM -
Real-World Evidence Study on the Resource Impact of Subcutaneous vs. Intravenous Atezolizumab in an NHS Cancer Center
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective
Sep 9, 2025, 16:22 PM -
Integrating Real-World Evidence for Advanced Therapies in Inflammatory Bowel Disease Into Reimbursement Submissions: Insights and Considerations From the UK
Sep 9, 2025, 16:22 PM -
Do We Need to Measure Social Impact of Innovative Drugs?
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective
Sep 9, 2025, 16:22 PM
